A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

Webinar Series: KNCV’s Patient Triage Approach 


Please join RESIST-TB on Thursday, January 25th from 08:00 – 09:00 EST (14:00 – 15:00 CET; 15:00 – 16:00 SAST) for an exciting webinar about KNCV’s Patient Triage Approach. Dr. Susan van den Hof will be our presenter.

KNCV Tuberculosis Foundation developed the Patient Triage Concept to ensure rapid diagnosis of TB and all forms of DR-TB (i.e. using rapid diagnostics) followed by early initiation of the most effective treatment regimen for every TB/DR-TB patient. KNCV team will present the methodology of the Right Diagnosis, Right Treatment Approach, and will share experiences with implementation of the shorter treatment regimen (STR) and individualized treatment regimens (ITR) containing new (bedaquiline, delamanid) and repurposed drugs in several countries under the Challenge TB project. During this webinar, KNCV will also share tools developed to assist countries in effectively introducing new drugs and regimens for DR-TB within their own context.
——————————————————-
To join the event as an attendee
——————————————————-
1. Go to https://hms.webex.com/hms/onstage/g.php?MTID=ebc7b47aa2806fb41a626b945a25d57f8
2. Click “Join Now”.

——————————————————-
To join the audio conference only
——————————————————-
Call-in toll number (US/Canada): 1-408-792-6300
Global call-in numbers: https://hms.webex.com/hms/globalcallin.php?serviceType=EC&ED=611583927&tollFree=0
Toll-free dialing restrictions: https://www.webex.com/pdf/tollfree_restrictions.pdf
Access code: 711 087 931
Event password: RIGHT
——————————————————
For assistance
——————————————————-
To contact your host, RESIST-TB, send a message to smcanaw@pih.org or beatrice_antoine@hms.harvard.edu

The playback of UCF (Universal Communications Format) rich media files requires appropriate players. To view this type of rich media files in the meeting, please check whether you have the players installed on your computer by going to https://hms.webex.com/hms/onstage/systemdiagnosis.php

https://www.webex.com

IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.

Recent News and Announcements

WHO issues a position statement on the use of delamanid for MDR-TB following an expedited review of phase III clinical trial results

This Position Statement by the World Health Organization (WHO) on the use of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB) has been developed in response to the final data from the phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of delamanid (Trial #242-09-213, hereafter referred to as ‘Trial 213’). […]

Webinar Series: New XDR-TB Regimens containing Pretomanid, January 11th

On Thursday, January 11, 2018 by Dr. Dan Everitt, Vice President and Senior Medical Officer at TB Alliance, presented on New XDR-TB Regimens containing Pretomanid. Dr. Dan Everitt, MD, of the Global Alliance presented the results of an important study of a six-month treatment regimen for XDR-TB using bedaquiline, pretomanid and linezolid, the NiX-TB trial. In addition, the […]

Health ministry approves new tuberculosis drug

“New Delhi: Perturbed by the increasing number of multi-drug resistant (MDR) and extensive drug resistant (XDR) tuberculosis cases in India, the health ministry has approved the use of a new drug in the treatment of such cases. The technical group on tuberculosis in the ministry of health has given approval to Delamanid, which is in […]

STREAM MDR-TB Clinical Trial: Results of comparison of 9-Month Treatment Regimen to 20-24 month regimen.

Dr. I.D. Rusen, MD, of the MRC presented the preliminary results from Stage 1 of the STREAM randomized clinical trial on Thursday, December 14th from 10:00 – 11:00 EST (16:00 – 17:00 CET; 17:00 – 18:00 SAST). The STREAM Clinical Trial team, including Andrew Nunn and Patrick Philips (Medical Research Council’s Clinical Trials Unit at UCL) and I.D. Rusen […]

Drug-Resistant Tuberculosis to Increase in 4 High-Burden Countries

Drug-resistant tuberculosis cases are on the rise in Russia, India, the Philippines, and South Africa and expected to increase through 2040. Additional strategies to prevent transmission will be necessary to stop multidrug-resistant or extensively drug-resistant tuberculosis in countries with a high burden of MDR tuberculosis. Watch the video found here to find out more.

Event Calendar

Social Media